Humanigen Inc (HGENQ)

OTCMKTS: HGENQ · Delayed Price · USD
0.0001
0.00 (0.00%)
Mar 1, 2024, 4:00 PM EST - Market closed
Market Cap 23.82K
Revenue (ttm) 1.70M
Net Income (ttm) -53.63M
Shares Out 119.08M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE 9.39
Dividend n/a
Ex-Dividend Date n/a
Volume 4,267
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range n/a
Beta -1.05
Analysts n/a
Price Target n/a
Earnings Date n/a

About HGENQ

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2013
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol HGENQ
Full Company Profile

Financial Performance

In 2022, Humanigen's revenue was $2.51 million, a decrease of -30.07% compared to the previous year's $3.60 million. Losses were -$70.73 million, -70.11% less than in 2021.

Financial Statements

News

Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement

NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ:HGEN). The ...

3 days ago - Accesswire

COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy

Drug developer Humanigen HGEN.PK has filed for voluntary Chapter 11 bankruptcy, according to a court filing, after struggling to get regulatory approval for its COVID-19 treatment.

2 months ago - Reuters

Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation

The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high...

7 months ago - Newsfile Corp

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon ...

9 months ago - Newsfile Corp

Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis Eleven subjects dosed with lenzilumab and with current standard of care, azacitidine S...

11 months ago - Newsfile Corp

Humanigen Reports Third Quarter 2022 Financial Results

Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first...

1 year ago - Newsfile Corp

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain infl...

1 year ago - Newsfile Corp

Humanigen Announces Retention of SC&H Capital as Financial Advisor

Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain infla...

1 year ago - Newsfile Corp

HGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 25, 2022 in the Class Action Filed on Behalf of Humanigen, Inc. Shareholders

NEW YORK , Oct. 25, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN) alleging that the Company...

1 year ago - PRNewsWire

HGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Humanigen, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

New York, New York--(Newsfile Corp. - October 24, 2022) - Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit...

1 year ago - Newsfile Corp

HGEN DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 16, 2020 and July 12...

1 year ago - PRNewsWire

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Humanigen Investors of a Lead Plaintiff Deadline of October 25, 2022

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Attention Humanigen, Inc. ("Humanigen") (NASDAQ: HGEN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on beha...

1 year ago - PRNewsWire

Humanigen Class Action: Levi & Korsinsky Reminds Humanigen, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 25, 2022 - HGEN

New York, New York--(Newsfile Corp. - October 23, 2022) - Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit...

1 year ago - Newsfile Corp

HGEN FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN

New York, New York--(Newsfile Corp. - October 22, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 16,...

1 year ago - Newsfile Corp

HGEN SHAREHOLDER ALERT: Jakubowitz Law Reminds Humanigen Shareholders of a Lead Plaintiff Deadline of October 25, 2022

NEW YORK , Oct. 21, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN). To receive upd...

1 year ago - PRNewsWire

HUMANIGEN, INC. (HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Humanigen, Inc. (HGEN)

Did you lose money on investments in Humanigen? If so, please visit Humanigen, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your...

1 year ago - Newsfile Corp

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN)

NEW YORK , Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humanigen, Inc.. Shareholders who purchased shares of HGEN during the class period listed are...

1 year ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Humanigen, Inc. of Class Action Lawsuit and upcoming Deadline - HGEN

NEW YORK , Oct. 19, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) and certain of its off...

1 year ago - PRNewsWire

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action – HGEN

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both d...

1 year ago - Business Wire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action - HGEN

NEW YORK , Oct. 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12...

1 year ago - PRNewsWire

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors With Losses to Secure Counsel Before Important October 25 Deadline in Securities Class Action - HGEN

New York, New York--(Newsfile Corp. - October 15, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28,...

1 year ago - Newsfile Corp

Humanigen Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 25, 2022 to Discuss Your Rights - HGEN

New York, New York--(Newsfile Corp. - October 14, 2022) - Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit...

1 year ago - Newsfile Corp

ROSEN, Leading Investor Counsel, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN

New York, New York--(Newsfile Corp. - October 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28,...

1 year ago - Newsfile Corp

ROSEN, Top Ranked Investor Counsel, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN

New York, New York--(Newsfile Corp. - October 9, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, ...

1 year ago - Newsfile Corp

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN

NEW YORK , Oct. 7, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12,...

1 year ago - PRNewsWire